SBIR Phase I: Development of novel SMP-based embolic coils

Information

  • NSF Award
  • 0912765
Owner
  • Award Id
    0912765
  • Award Effective Date
    7/1/2009 - 15 years ago
  • Award Expiration Date
    12/31/2009 - 15 years ago
  • Award Amount
    $ 100,000.00
  • Award Instrument
    Standard Grant

SBIR Phase I: Development of novel SMP-based embolic coils

This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).<br/><br/>This Small Business Innovation Research (SBIR) Phase I project aims to develop the next generation of vascular embolization coils using proprietary shape memory polymer (SMP) technology. Coils are used to occlude or isolate vessels for treatment of malformations, hemorrhage and tumor isolation. Current metal coils are expensive, cannot effectively occlude large vessels, and exhibit limitations resulting in long procedures. EndoShape's (ESI) SMP technologies promise to significantly reduce device cost, reduce procedure time, achieve large vessel closure, while enabling a broad set of medical procedures. This project leverages previous material research from the University of Colorado, combined with ESI's ongoing development work on device design and SMP manufacturing technology. To optimize design, we focus on: resistance to migration, fatigue, and biocompatibility. By employing finite element analysis, in vitro testing and animal evaluation, we efficiently distill many design and material combinations to the most promising candidates. Phase I work will pursue a sub-set of these goals.<br/><br/>The broader impacts of this research are providing physicians with more effective and more cost efficient devices that can be adapted to an expanded patient population and a broader set of medical procedures. A direct benefit of an SMP embolic coil is an expanded indication for use in pediatrics, or neurovascular intervention, wherein current metal coils have limited utility or present compromises (e.g. imaging artifacts) associated with their material. Further clinical advances through integration of tissue engineering or development of patient specific devices can be leveraged from the success of these devices.

  • Program Officer
    Gregory T. Baxter
  • Min Amd Letter Date
    6/10/2009 - 15 years ago
  • Max Amd Letter Date
    9/25/2009 - 15 years ago
  • ARRA Amount
    100000

Institutions

  • Name
    EndoShape Inc
  • City
    Boulder
  • State
    CO
  • Country
    United States
  • Address
    2450 Central Avenue, Suite I
  • Postal Code
    803011527
  • Phone Number
    3036527338

Investigators

  • First Name
    Craig
  • Last Name
    Lanning
  • Email Address
    clanning@endoshape.com
  • Start Date
    6/10/2009 12:00:00 AM
  • End Date
    09/25/2009
  • First Name
    Julie
  • Last Name
    Trommeter
  • Email Address
    jtrommeter@endoshape.com
  • Start Date
    9/25/2009 12:00:00 AM

FOA Information

  • Name
    Industrial Technology
  • Code
    308000